-

Paige to Host Exhibitor Seminar and Product Demonstrations at USCAP 2022 Annual Meeting

Seminar to provide guidance to pathologists and laboratory professionals on the ethical development, rigorous validation, and importance regulatory governance of clinical AI applications

NEW YORK--(BUSINESS WIRE)--Paige, the global leader in AI-based diagnostic software in pathology, today announced it will participate in the United States and Canadian Academy of Pathology (USCAP) 2022 Annual Meeting, taking place virtually and in-person at the Los Angeles Convention Center in Los Angeles from March 19-24, 2022. David Klimstra, M.D., Founder and Chief Medical Officer, will join Juan Retamero, M.D., Medical Director, in hosting a seminar on clinical AI applications in pathology and their role in improving patient safety. Paige will also provide an overview and hands-on demonstration of its products, including FDA-approved Paige Prostate Detect, at booth #816 from March 21-23, 2022.

Additionally, Paige Prostate Detect, Paige Prostate Grade and Quantify and Paige Prostate Perineural Invasion will be featured as part of the New Product Display in the exhibit hall beginning March 21, 2022. New Product Displays spotlight innovative pathology products based on specific eligibility criteria.

Please follow us on Twitter and LinkedIn for conference-related content we will be sharing throughout USCAP.

About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., David Klimstra, M.D., and colleagues from Memorial Sloan Kettering Cancer Center (MSK). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA approval for an AI-based digital pathology product.

For additional information, please visit: https://www.paige.ai, Twitter and LinkedIn.

Contacts

Paige Media:
Jon Yu
ICR Westwicke
Tel: 475.395.5375
Jon.Yu@westwicke.com

Industry:

Paige

Release Versions
English

Contacts

Paige Media:
Jon Yu
ICR Westwicke
Tel: 475.395.5375
Jon.Yu@westwicke.com

More News From Paige

Paige Publishes Data Supporting First FDA-Authorized AI Software for Digital Pathology

NEW YORK--(BUSINESS WIRE)--Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, today announced it has published the results of a pivotal study demonstrating accuracy gains in pathologists’ diagnosis of prostate cancer when using Paige Prostate Detect, an FDA-authorized AI software that assists pathologists in the detection of foci that are suspicious for cancer during the review of scanned whole slide images (WSI) from prostate needle biopsies. The res...

University Medical Center Utrecht Partners with Paige to Conduct Health Economics Study and to Evaluate AI in Clinical Setting

NEW YORK--(BUSINESS WIRE)--Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, today announced it has entered into a multi-stage research agreement with the University Medical Center (UMC) Utrecht in the Netherlands. UMC Utrecht will deploy Paige AI applications for routine clinical use and conduct a clinical health economics study to support the adoption and reimbursement of AI applications in pathology. The prospective CONFIDENT clinical study will e...

Paige and OptraSCAN Partner to Streamline Digital Pathology Adoption

NEW YORK--(BUSINESS WIRE)--Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, and OptraSCAN®, a leading producer of whole slide scanners, today announced a partnership to streamline the adoption of digital pathology technology in the United States, European Union countries and United Kingdom. The companies aim to reduce barriers to digitizing glass pathology slides, which will in turn enhance workflows in pathology and oncology. Together, the companie...
Back to Newsroom